Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $11.55.
→ The Stock That Is Flying Under Wall St. Radar (From Upexi, Inc)
Several equities research analysts have recently weighed in on HIMS shares. Truist Financial increased their price target on Hims & Hers Health from $7.00 to $12.00 and gave the company a “hold” rating in a research note on Tuesday, February 28th. Jefferies Financial Group raised Hims & Hers Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $7.00 to $11.00 in a research note on Thursday, February 9th. Credit Suisse Group raised their target price on Hims & Hers Health from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Citigroup raised their target price on Hims & Hers Health from $9.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, February 28th. Finally, Piper Sandler raised their target price on Hims & Hers Health from $7.00 to $10.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 28th.
Hims & Hers Health Trading Up 3.8 %
Shares of HIMS stock opened at $10.03 on Wednesday. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -31.34 and a beta of 0.49. The stock has a 50-day moving average of $8.88 and a 200-day moving average of $6.89. Hims & Hers Health has a 1-year low of $2.72 and a 1-year high of $12.04.
Hims & Hers Health (NYSE:HIMS – Get Rating) last issued its quarterly earnings results on Monday, February 27th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $167.30 million during the quarter, compared to analysts’ expectations of $161.18 million. Hims & Hers Health had a negative return on equity of 20.69% and a negative net margin of 12.47%. The business’s quarterly revenue was up 97.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. Sell-side analysts forecast that Hims & Hers Health will post -0.13 earnings per share for the current year.
Insiders Place Their Bets
In other Hims & Hers Health news, insider Soleil Boughton sold 50,000 shares of the stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $8.14, for a total value of $407,000.00. Following the transaction, the insider now owns 237,089 shares in the company, valued at $1,929,904.46. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Alex Bard sold 500,000 shares of the stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $11.55, for a total value of $5,775,000.00. Following the completion of the sale, the director now directly owns 296,878 shares of the company’s stock, valued at approximately $3,428,940.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 50,000 shares of the firm’s stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $8.14, for a total value of $407,000.00. Following the transaction, the insider now owns 237,089 shares in the company, valued at $1,929,904.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 695,166 shares of company stock worth $7,595,112. Corporate insiders own 35.22% of the company’s stock.
Institutional Investors Weigh In On Hims & Hers Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP increased its position in shares of Hims & Hers Health by 99.4% during the 4th quarter. Marshall Wace LLP now owns 4,487,038 shares of the company’s stock valued at $28,762,000 after purchasing an additional 2,236,609 shares during the last quarter. Foresite Capital Management V LLC grew its position in Hims & Hers Health by 21.7% during the fourth quarter. Foresite Capital Management V LLC now owns 4,041,383 shares of the company’s stock valued at $25,905,000 after buying an additional 721,597 shares during the period. Millennium Management LLC increased its holdings in Hims & Hers Health by 145.8% during the fourth quarter. Millennium Management LLC now owns 3,524,750 shares of the company’s stock worth $22,594,000 after buying an additional 2,090,833 shares during the last quarter. State Street Corp raised its position in Hims & Hers Health by 16.3% in the third quarter. State Street Corp now owns 3,021,045 shares of the company’s stock worth $16,857,000 after acquiring an additional 423,361 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Hims & Hers Health by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 2,193,273 shares of the company’s stock valued at $14,058,000 after acquiring an additional 76,928 shares during the last quarter. Hedge funds and other institutional investors own 45.60% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Hims & Hers Health wasn’t on the list.
While Hims & Hers Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
